Abstract

Ambient artificial intelligence (AI) scribe technology is entering clinical settings with the promise of reducing documentation burden. For health system leaders, these tools pose governance challenges rather than simple information technology upgrades. Early pilots show reductions of up to 30% in after-hours charting, but results vary with implementation quality. This article argues that Canada should classify AI scribes as Class II Software as a Medical Device and outlines governance questions for executives and boards. By treating ambient AI scribes as strategic leadership priorities – rather than technology deployments – healthcare leaders can balance efficiency with ethical stewardship and strengthen patient trust.